Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | glycoprotein hormones, alpha polypeptide | Starlite/ChEMBL | No references |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Toxoplasma gondii | intraflagellar transport protein 172, putative | glycoprotein hormones, alpha polypeptide | 116 aa | 94 aa | 26.6 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Brugia malayi | Matrixin family protein | 0.0435 | 0.2064 | 0.2556 |
Loa Loa (eye worm) | matrixin family protein | 0.1126 | 0.6553 | 1 |
Echinococcus multilocularis | adam 17 protease | 0.0188 | 0.0455 | 0.0455 |
Loa Loa (eye worm) | hypothetical protein | 0.0435 | 0.2064 | 0.2556 |
Loa Loa (eye worm) | matrix metalloproteinase | 0.0435 | 0.2064 | 0.2556 |
Echinococcus multilocularis | matrix metallopeptidase 7 (M10 family) | 0.1656 | 1 | 1 |
Mycobacterium ulcerans | hydrolase | 0.053 | 0.268 | 0.5 |
Echinococcus granulosus | adam 17 protease | 0.0207 | 0.0577 | 0.0577 |
Brugia malayi | Matrix metalloprotease, N-terminal domain containing protein | 0.053 | 0.268 | 0.3578 |
Mycobacterium leprae | PROBABLE HYDROLASE | 0.053 | 0.268 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0435 | 0.2064 | 0.2556 |
Brugia malayi | Matrixin family protein | 0.0435 | 0.2064 | 0.2556 |
Loa Loa (eye worm) | matrixin family protein | 0.0965 | 0.5511 | 0.8271 |
Schistosoma mansoni | matrix metallopeptidase-7 (M10 family) | 0.0509 | 0.254 | 0.676 |
Schistosoma mansoni | matrix metallopeptidase-9 (M10 family) | 0.0673 | 0.3609 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0395 | 0.18 | 0.2119 |
Loa Loa (eye worm) | hypothetical protein | 0.0509 | 0.254 | 0.3346 |
Brugia malayi | Matrixin family protein | 0.0435 | 0.2064 | 0.2556 |
Echinococcus multilocularis | a disintegrin and metalloproteinase with | 0.0166 | 0.0311 | 0.0311 |
Schistosoma mansoni | hypothetical protein | 0.0617 | 0.3246 | 0.8901 |
Loa Loa (eye worm) | hypothetical protein | 0.053 | 0.268 | 0.3578 |
Mycobacterium tuberculosis | Probable peptidoglycan hydrolase | 0.053 | 0.268 | 0.5 |
Schistosoma mansoni | ADAM17 peptidase (M12 family) | 0.0188 | 0.0455 | 0.0437 |
Brugia malayi | Hemopexin family protein | 0.0617 | 0.3246 | 0.4517 |
Echinococcus granulosus | a disintegrin and metalloproteinase with | 0.0166 | 0.0311 | 0.0311 |
Brugia malayi | Matrixin family protein | 0.0435 | 0.2064 | 0.2556 |
Brugia malayi | Matrixin family protein | 0.1126 | 0.6553 | 1 |
Onchocerca volvulus | 0.0617 | 0.3246 | 0.3015 | |
Onchocerca volvulus | Matrilysin homolog | 0.1039 | 0.5987 | 1 |
Onchocerca volvulus | Matrix metalloproteinase homolog | 0.0965 | 0.5511 | 0.8785 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | 5.0119 uM | PubChem BioAssay. qHTS for Activators of Integrin-Mediated Alleviation for Muscular Dystrophy. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 18.526 uM | PUBCHEM_BIOASSAY: Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 96 hour incubation. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488745, AID488752, AID488774, AID504848, AID504850] | ChEMBL. | No reference |
Potency (functional) | 20.5878 uM | PUBCHEM_BIOASSAY: qHTS screen for small molecules that inhibit ELG1-dependent DNA repair in human embryonic kidney (HEK293T) cells expressing luciferase-tagged ELG1. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID493107, AID493125] | ChEMBL. | No reference |
Potency (functional) | 100 uM | PUBCHEM_BIOASSAY: HTS for Inhibitors of HP1-beta Chromodomain Interactions with Methylated Histone Tails. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488962] | ChEMBL. | No reference |
Species name | Source | Reference | Is orphan |
---|---|---|---|
Plasmodium falciparum | ChEMBL23 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.